GSK2857916 showed more selective and potent anti-MM killing than its monomethyl auristatin E (MMAE) ADC homolog in the preclinical study, thereby moving forward to the first clinical trial of BCMA-targeting ADC in MM [83,95]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.